Wachtell Kristian, Dahlöf Björn, Rokkedal Jens, Papademetriou Vasilious, Nieminen Markku S, Smith Gunnar, Gerdts Eva, Boman Kurt, Bella Jonathan N, Devereux Richard B
Department of Medicine, Copenhagen County University Hospital, Glostrup, Denmark.
Am Heart J. 2002 Dec;144(6):1057-64. doi: 10.1067/mhj.2002.126113.
Patients with hypertension have different types of left ventricular (LV) geometry, but the impact of blood pressure (BP) reduction on LV geometry change during antihypertensive treatment remains unclear.
Two-dimensional and M-mode echocardiograms were recorded at baseline in 853 unmedicated patients with stage II to III hypertension and LV hypertrophy determined by electrocardiography (Cornell voltage duration > or =2440 mV x ms or modified Sokolow-Lyon criteria: SV1 + RV5/RV6 >38 mV) after 14 days of placebo treatment. Follow-up echocardiography was done after 1 year of blinded treatment with either losartan or atenolol, in some cases supplemented with thiazide and calcium antagonist to reach target a BP of 140/90 mm Hg.
Baseline systolic/diastolic BP were reduced from 174 +/- 20/95 +/- 11 to 151 +/- 19/84 +/- 11 mm Hg. LV mass was reduced from 234 +/- 56 to 207 +/- 51 g and relative wall thickness from 0.41 +/- 0.07 to 0.38 +/- 0.06 (all P <.001). Prevalence of concentric LV hypertrophy decreased from 24% to 6%, eccentric LV hypertrophy from 46% to 37%, and concentric LV remodeling from 10% to 6%; normal geometry increased from 20% to 51%. A shift toward lower LV mass and relative wall thickness was found, as approximately 73% of those with concentric LV remodeling at baseline shifted to normal geometric pattern, whereas only 7% of those with normal pattern at baseline shifted to concentric LV remodeling. Of patients with concentric LV hypertrophy at baseline, 34% shifted to eccentric LV hypertrophy, whereas only 3% with eccentric LV hypertrophy at baseline had concentric LV hypertrophy. Furthermore, multiple regression analysis showed that Doppler stroke volume reduction was a significant correlate of LV mass reduction (beta = 0.108, P <.001) independent of BP, heart rate change, and assigned drug treatment.
Antihypertensive treatment reduces LV mass and decreases the prevalence of LV hypertrophy and concentric LV remodeling. Additional control of Doppler stroke volume potentiates the effect of BP reduction on LV mass regression independent of the BP reduction per se.
高血压患者有不同类型的左心室(LV)几何形态,但血压(BP)降低对抗高血压治疗期间LV几何形态变化的影响仍不清楚。
在853例未经药物治疗的II至III期高血压患者中,在基线时记录二维和M型超声心动图,并在安慰剂治疗14天后通过心电图确定LV肥厚(康奈尔电压持续时间>或=2440 mV×ms或改良的索科洛夫-里昂标准:SV1 + RV5/RV6>38 mV)。在用氯沙坦或阿替洛尔进行1年盲法治疗后进行随访超声心动图检查,在某些情况下补充噻嗪类和钙拮抗剂以使血压目标达到140/90 mmHg。
基线收缩压/舒张压从174±20/95±11降至151±19/84±11 mmHg。LV质量从234±56降至207±51 g,相对壁厚度从0.41±0.07降至0.38±0.06(所有P<.001)。同心性LV肥厚的患病率从24%降至6%,离心性LV肥厚从46%降至37%,同心性LV重构从10%降至6%;正常几何形态从20%增加到51%。发现向较低的LV质量和相对壁厚度转变,因为基线时约73%的同心性LV重构患者转变为正常几何形态模式,而基线时正常模式的患者中只有7%转变为同心性LV重构。基线时同心性LV肥厚的患者中,34%转变为离心性LV肥厚,而基线时离心性LV肥厚的患者中只有3%有同心性LV肥厚。此外,多元回归分析表明,多普勒每搏量减少是LV质量减少的显著相关因素(β=0.108,P<.001),与血压、心率变化和指定的药物治疗无关。
抗高血压治疗可降低LV质量并降低LV肥厚和同心性LV重构的患病率。对多普勒每搏量的额外控制可增强血压降低对LV质量回归的作用,而与血压降低本身无关。